Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, triptorelin acetate (Decapeptyl®) cannot be endorsed for use within NHS Wales as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine-responsive early-stage breast cancer in women at high-risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy. |
||
|
||
Medicine details |
||
| Medicine name | triptorelin acetate (Decapeptyl®) | |
| Formulation | 3 mg powder for suspension for injection | |
| Reference number | 3076 | |
| Indication | For use as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine-responsive early-stage breast cancer in women at high-risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy |
|
| Company | Ipsen Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 12/07/2017 | |
| Date of issue | 13/07/2017 | |